JPRN-UMIN000005284
Completed
Phase 2
Phase2 study of Carboplatin / Paclitaxel + Bevacizumab to non-small-cell lung cancer (non-squamous cell carcinoma) with pleural efussion in stage4 - Phase2 study of CBDCA / PTX + Bevacizumab to non-small-cell lung cancer with pleural efussion
Osaka Prefectural Medical Center for Respiratory and Allergic diseases0 sites20 target enrollmentMarch 22, 2011
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- non-small-cell lung cancer (non-squamous cell carcinoma) with pleural efussion in stage4
- Sponsor
- Osaka Prefectural Medical Center for Respiratory and Allergic diseases
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)History of pleurodesis 2\)Severe infection except for non\-active hepatitis C 3\)Fever more than 38 degree 4\)Severe comorbidity (heart failure/kidney failure/hepatic failure/uncontrollable diabetes/uncontrollable hypertension, etc) 5\)Active double cancer 6\)Symptomatic brain metastasis 7\)History of hemoptysis with 2\.5mL or more 8\)Pericardial effusion requiring drainage 9\)Interstitial pneumonia or pulmonary fibrosis detectable on X ray 10\)History of drug sensitivity 11\)Pregnant or lactating women 12\)Psychiatric disease or mental trouble 13\)Continuing administration of steroid 14\)Evaluated to be ineligible by a physician for other reasons
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Phase2 study of Carboplatin / Nab-paclitaxel + Bevacizumab to non-small-cell lung cancer (non-squamous cell carcinoma) with malignant pleural efussionon-small-cell lung cancer (non-squamous cell carcinoma) with malignant pleural efussion in stage4JPRN-UMIN000013329Osaka Prefectural Medical Center for Respiratory and Allergic diseases20
Active, not recruiting
Not Applicable
A phase II study of carboplatin –paclitaxel with bevacizumab followed by the addition of erlotinib to bevacizumab beyond progression in patients with locally advanced and/or metastatic non-small cell lung cancer (NSCLC) who have not received prior systemic therapy. - bevacizumab plus erlotinib beyond progressioEUCTR2007-005523-15-NLRadboud University Medical Centre
Completed
Phase 2
Phase II Study of Paclitaxel and Carboplatin plus Bevacizumab in StageIIIA-N2, IIIB, IV patients with Nonsquamous Non-Small-Cell Lung Cancerchemotherapy-na&iumlve StageIIIA-N2, IIIB, IV patients with nonsquamous non-small-cell lung cancerJPRN-UMIN000006809Akita University Graduate School of Medicine31
Completed
Phase 2
Phase II study of Carboplatin, Paclitaxel and Bevacizumab in patients with advanced Non-squamous non-small-cell lung cancer with large malignant pleural effusion.JPRN-UMIN000006767Shizuoka Cancer Center32
Recruiting
Phase 2
A Phase II study of Paclitaxel plus Carboplatin plus Bevacizumab that introduces concept of Clinical PD in recurrent or advanced non-squamous non-small cell lung cancer.recurrent or advanced non-squamous non-small-cell and lung cancer.JPRN-UMIN000005328Dept. of Respiratory Medicine, Osaka University Hospital45